“I was keen to go on a clinical trial. I wanted to try new cancer treatments and hopefully help future generations.”
A trial looking at zoledronic acid to try to stop breast cancer coming back (AZURE)
This trial looked at whether zoledronic acid helps to stop breast cancer coming back. This trial was supported by Cancer Research UK.
More about this trial
Doctors usually treat breast cancer with surgery and then one or more of the following standard treatments - radiotherapy, chemotherapy, biological therapy and hormone therapy.
Zoledronic acid (Zometa) is one of a group of drugs called bisphosphonates. Bisphosphonates are often used to control symptoms caused by cancer that has spread to the bone. Doctors hoped that if women had zoledronic acid after surgery, it would help stop the cancer coming back.
All the women who took part in this trial had standard treatment after surgery. One group had zoledronic acid as well, and the other group didn’t.
The aim of this trial was to see if zoledronic acid helped stop breast cancer coming back.
Summary of results
The research team found that overall, adding zoledronic acid to standard treatment for breast cancer doesn’t help stop the cancer coming back. But women who had already been through the menopause did have a small, but important, benefit.
This was a large phase 3 trial. It recruited over 3,300 women from 174 hospitals in 7 countries. Everyone taking part had had (or were due to have) surgery for breast cancer that hadn’t spread to another part of the body.
They were recruited into 1 of 2 groups
- 1,678 were in group 1 (the control group) and had standard treatment
- 1,681 were in group 2 and had standard treatment and zoledronic acid
The women in group 2 had zoledronic acid every 3 to 4 weeks for the first 6 doses, and then every 3 to 6 months up to a total of 5 years.
The research team looked at the results in 2013 to see how many women had cancer that had started to grow again. They found there was no real difference between the 2 groups about 7 years after joining the trial. There was no sign of cancer in about 68 out of every 100 women (68%) in each group.
They also looked at how many women were still alive at this time. Again, there was little difference between the 2 groups, with about 79 out of every 100 women (79%) in each group alive.
When the research team looked at the results in more detail they found that women who had been through the menopause before they were diagnosed with breast cancer did have some benefit from zoledronic acid. Unfortunately, younger women who hadn’t been through (or were still going through) the menopause when they were diagnosed didn’t have the same benefit.
The research team looked at the results of the 1,041 women who had been through the menopause more than 5 years before joining the trial. They found that there was no sign of cancer 7 years after joining the trial in
- 69 out of every 100 women (69%) who had zoledronic acid
- 64 out of every 100 women (64%) who didn’t have zoledronic acid
They also looked at how many women were living 7 years after being joining the trial, and found it was
- 78 out of every 100 women (78%) who had zoledronic acid
- 74 out of every 100 women (74%) who didn’t have zoledronic acid
26 women in the zoledronic acid group had a side effect called osteonecrosis of the jaw. There were another 7 possible but unconfirmed cases. No one in the control group had this side effect.
The trial team looked at the number of bone fractures in each group in 2011.They found there were fewer bone fractures in zoledronic acid group – 65, compared to 110 in the control group.
The research team concluded, on balance, that zoledronic acid is a useful treatment for older women who have been through the menopause before they are diagnosed with breast cancer.
We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Robert Coleman
Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
National Institute for Health Research Cancer Research Network (NCRN)
This is Cancer Research UK trial number CRUKE/03/017